Given a document and an entity the task is to select the author's sentiment towards the entity. Sentiments can be Positive, Neutral and Negative. Select Positive if the article expresses a positive view towards the given entity or praises its quality or skills. Select Neutral if the document expresses no clear view towards the entity or has equal amounts of positive and negative statements or expressing some fact/quote by someone else. Select Negative if the article expresses a negative view towards like harsh remarks, criticizing entities action/decision etc. Note that URLs in the text have been replaced with [Link].

[Q]: What is the sentiment of the following document towards the entity Ablynx ? PARIS/LONDON (Reuters) - French drugmaker Sanofi has agreed to buy  Belgian biotech company Ablynx  for 3.9 billion euros ($4.8 billion)  beating Novo Nordisk and marking its second big deal this month after buying Bioverativ.
The deal is a further sign of accelerating merger and acquisition (M&A) activity in the global biotech sector and comes after  Ablynx  rejected a 2.6 billion euro offer from Denmark’s Novo Nordisk.
Sanofi said on Monday it would pay 45 euros per share in cash for Ablynx  a premium of 21 percent over its closing price on Friday - and more than double the price before Novo went public with its initial bid.
Novo Nordisk conceded defeat  saying it did not intend to make a revised offer for Ablynx  which is developing a prized experimental drug for a rare blood disorder.
Sanofi said  Ablynx  would boost long-term value for  its  shareholders  while the takeover was expected to have a neutral impact on Sanofi’s business earnings per share (EPS) in 2018 and 2019.
Sanofi is already one of  Ablynx ’s big pharma partners  after striking a deal in July 2017 to find new treatments for inflammatory diseases.
By buying the company outright it will now get access to  Ablynx ’s most promising asset  the experimental drug caplacizumab for treating the rare bleeding disorder acquired thrombotic thrombocytopenic purpura.
Sanofi will be able to use its existing infrastructure and the recently acquired platform from Bioverativ to help to commercialize caplacizumab. It will also benefit from some of the other drugs  Ablynx  is working on  such as an infant anti-viral treatment  that would not have fitted within Novo Nordisk.
Berenberg analysts said  Ablynx  was a good fit but they estimated the deal would generate no more than a 4 percent return on invested capital  assuming caplacizumab sales of around 400 million euros by 2023.
The Danish group has sat out previous rounds of M&A in the drugs sector to focus on its core diabetes business but it now needs to find new products for its struggling smaller biopharmaceutical unit  where Ablynx would have been a good fit.
Morgan Stanley and Lazard advised Sanofi on the deal while JP Morgan advised Ablynx.
[A]: Positive


[Q]: What is the sentiment of the following document towards the entity Bahtiyar Duysak ? TechCrunch  the industry website owned by AOL  has tracked down the ex-Twitter employee it says is responsible for the Nov. 2 incident: His name is  Bahtiyar Duysak   and he is described by the tech site as "a twenty-something with Turkish roots who was born and raised in Germany."
Twitter has declined to confirm his identity. However   Duysak  says he was a contractor at management services company Pro Unlimited and had been assigned to Twitter's Trust and Safety division  the department that sorts through alerts from users reporting abusive behavior or violations of the company's terms of service.
On his last day at Twitter HQ in San Francisco   Duysak  says  he  received a report on the president's account. TechCrunch writes: "as a final  throwaway gesture   he  put the wheels in motion to deactivate it. Then  he  closed  his  computer and left the building."
 He  says  he  didn't think the account would actually be deactivated and  in any case  calls the whole thing a "mistake."
However   Duysak  contends that  he  didn't do anything wrong either. "I didn't hack anyone "  he  tells the tech site. "I didn't break any rules."
 He  said as a consequence of  his  actions   he 's been hounded by reporters on social media and that  he  hopes by coming forward  he  can clear the air and "continue an ordinary life."
[A]: Positive


[Q]: What is the sentiment of the following document towards the entity Joachim Frank ? The 2017 Nobel Prize in chemistry has been awarded to  researchers Jacques Dubochet  Joachim Frank and Richard Henderson  for  their  work that developed cryo-electron microscopy  which the Royal Swedish Academy of Sciences says "both simplifies and improves the imaging of biomolecules."
Speaking to the prize committee by phone Wednesday morning   Frank  said  he  had thought the chance of  him  winning the prestigious honor was "minuscule."
 He  added that cryo-electron microscopy "is about to completely transform structural biology " saying the technology is being taken up by a new generation of medical researchers.
Dubochet is affiliated with the University of Lausanne  in Switzerland;  Frank  is affiliated with Columbia University in New York; Henderson is affiliated with the MRC Laboratory of Molecular Biology in Cambridge  U.K.
"Electron microscopes were long believed to only be suitable for imaging dead matter  because the powerful electron beam destroys biological material. But in 1990  Richard Henderson succeeded in using an electron microscope to generate a three-dimensional image of a protein at atomic resolution. This breakthrough proved the technology's potential. " Joachim Frank  made the technology generally applicable. Between 1975 and 1986  he  developed an image processing method in which the electron microscope's fuzzy twodimensional images are analysed and merged to reveal a sharp three-dimensional structure. "Jacques Dubochet added water to electron microscopy. Liquid water evaporates in the electron microscope's vacuum  which makes the biomolecules collapse. In the early 1980s  Dubochet succeeded in vitrifying water â  he  cooled water so rapidly that it solidified in its liquid form around a biological sample  allowing the biomolecules to retain their natural shape even in a vacuum."
[A]:
Positive